Age: 55.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Vaccination site warmth
Clinical narrative: Injection site was red, warm/hot, slightly itchy.; Injection site was red, warm/hot, slightly itchy.; Injection site was red, warm/hot, slightly itchy.; Patient received dose 4: Moderna; dose 5: BNT162B2, BNT162B2 OMI BA.4-5; Patient received dose 4: Moderna; dose 5: BNT162B2, BNT162B2 OMI BA.4-5; CSL vaccine given on same day as Bivalent vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 03Nov2022 at 19:45 as dose 5 (booster), single (Lot number: GJ2524) at the age of 55 years, in right arm for covid-19 immunisation; influenza vaccine (CSL), on 03Nov2022 as dose 1, single (Batch/Lot number: unknown), in right arm for immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "Known allergies: Sulfa" (unspecified if ongoing); "COVID-19" (unspecified if ongoing), notes: If covid prior vaccination: Yes. Concomitant medication(s) included: DIFLUCAN; XYZAL; PEPCID [FAMOTIDINE]. Past drug history included: Demerol, reaction(s): "Known allergies: demerol". Vaccination history included: moderna (DOSE 4 (BOOSTER), SINGLE, Lot number: 001M21A, Anatomical location: Arm Right), administration date: 16Apr2022, when the patient was 54-year-old, for Covid-19 Immunization; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Lot number: FF2587, Anatomical location: Arm Right, ), administration date: 08Oct2021, when the patient was 54-year-old, for COVID-19 immunization; BNT162b2 (DOSE 2, SINGLE, Lot number: EW0158, Anatomical location: Arm Right, Vaccine Administration Time: 15:00), administration date: 09Apr2021, when the patient was 53-year-old, for COVID-19 immunization; BNT162b2 (DOSE 1, SINGLE, Lot number: EN6024, Anatomical location: Arm Right, Vaccine Administration Time: 15:00), administration date: 19Mar2021, when the patient was 53-year-old, for COVID-19 immunization. The following information was reported: PRODUCT USE ISSUE (non-serious) with onset 03Nov2022 at 19:45, outcome "unknown", described as "CSL vaccine given on same day as Bivalent vaccine"; OFF LABEL USE (non-serious), INTERCHANGE OF VACCINE PRODUCTS (non-serious) all with onset 03Nov2022 at 19:45, outcome "unknown" and all described as "Patient received dose 4: Moderna; dose 5: BNT162B2, BNT162B2 OMI BA.4-5"; VACCINATION SITE WARMTH (non-serious), VACCINATION SITE PRURITUS (non-serious), VACCINATION SITE ERYTHEMA (non-serious) all with onset 04Nov2022 at 08:00, outcome "recovering" and all described as "Injection site was red, warm/hot, slightly itchy.". The event "injection site was red, warm/hot, slightly itchy." required physician office visit. Therapeutic measures were taken as a result of vaccination site warmth, vaccination site pruritus, vaccination site erythema.  Additional information: The patient did not receive other vaccine in four weeks. Post covid, the patient had not tested. Treatment included Corticosteroid cream, benadryl and ice for the reported events.